GB0903325D0 - Antibody molecules - Google Patents

Antibody molecules

Info

Publication number
GB0903325D0
GB0903325D0 GBGB0903325.9A GB0903325A GB0903325D0 GB 0903325 D0 GB0903325 D0 GB 0903325D0 GB 0903325 A GB0903325 A GB 0903325A GB 0903325 D0 GB0903325 D0 GB 0903325D0
Authority
GB
United Kingdom
Prior art keywords
antibody molecules
antibody
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0903325.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Priority to GBGB0903325.9A priority Critical patent/GB0903325D0/en
Publication of GB0903325D0 publication Critical patent/GB0903325D0/en
Priority to US13/203,418 priority patent/US8697845B2/en
Priority to EP10706034.5A priority patent/EP2401035B1/en
Priority to ES10706034.5T priority patent/ES2662652T3/es
Priority to JP2011551521A priority patent/JP5864266B2/ja
Priority to AU2010217453A priority patent/AU2010217453B2/en
Priority to CA2772648A priority patent/CA2772648A1/en
Priority to CN201080018428.9A priority patent/CN102421482B/zh
Priority to PCT/GB2010/000351 priority patent/WO2010097597A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0903325.9A 2009-02-26 2009-02-26 Antibody molecules Ceased GB0903325D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0903325.9A GB0903325D0 (en) 2009-02-26 2009-02-26 Antibody molecules
US13/203,418 US8697845B2 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to a soluble form of CTLA-4
EP10706034.5A EP2401035B1 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of ctla-4
ES10706034.5T ES2662652T3 (es) 2009-02-26 2010-02-26 Anticuerpos específicamente dirigidos a la forma soluble de CTLA-4
JP2011551521A JP5864266B2 (ja) 2009-02-26 2010-02-26 可溶型のｃｔｌａ−４に特異的に対する抗体
AU2010217453A AU2010217453B2 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of CTLA-4
CA2772648A CA2772648A1 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of ctla-4
CN201080018428.9A CN102421482B (zh) 2009-02-26 2010-02-26 特异性针对可溶型ctla-4的抗体分子
PCT/GB2010/000351 WO2010097597A1 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of ctla-4

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0903325.9A GB0903325D0 (en) 2009-02-26 2009-02-26 Antibody molecules

Publications (1)

Publication Number Publication Date
GB0903325D0 true GB0903325D0 (en) 2009-04-08

Family

ID=40565800

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0903325.9A Ceased GB0903325D0 (en) 2009-02-26 2009-02-26 Antibody molecules

Country Status (9)

Country Link
US (1) US8697845B2 (https=)
EP (1) EP2401035B1 (https=)
JP (1) JP5864266B2 (https=)
CN (1) CN102421482B (https=)
AU (1) AU2010217453B2 (https=)
CA (1) CA2772648A1 (https=)
ES (1) ES2662652T3 (https=)
GB (1) GB0903325D0 (https=)
WO (1) WO2010097597A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
ES2979210T3 (es) * 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド がんの治療のためのｍＲＮＡ併用療法
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
AU2018227428A1 (en) * 2017-02-28 2019-10-17 Bristol-Myers Squibb Company Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
SG11202005692WA (en) * 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021009188A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021250594A1 (en) * 2020-06-11 2021-12-16 Nantbio, Inc. Anti-ctla4 monoclonal antibodies and chimeric antigen receptors
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US6107056A (en) * 1996-02-22 2000-08-22 Oaks; Martin K. SCTLA-4 gene and product
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2001255398A1 (en) * 2000-04-12 2001-10-30 Genetics Institute Inc. Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US20090252741A1 (en) * 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB0426644D0 (en) 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
US8110194B2 (en) * 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
WO2009008916A2 (en) * 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CN102421482A (zh) 2012-04-18
US20120107320A1 (en) 2012-05-03
JP5864266B2 (ja) 2016-02-17
CA2772648A1 (en) 2010-09-02
US8697845B2 (en) 2014-04-15
WO2010097597A1 (en) 2010-09-02
AU2010217453B2 (en) 2017-05-25
AU2010217453A1 (en) 2011-10-20
CN102421482B (zh) 2016-02-24
JP2012518425A (ja) 2012-08-16
ES2662652T3 (es) 2018-04-09
EP2401035A1 (en) 2012-01-04
EP2401035B1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
GB0903325D0 (en) Antibody molecules
IL211850A0 (en) Improved antibody molecules
SG10201401331TA (en) Anti-siglec-15 antibody
IL218544A0 (en) Dll4-binding molecules
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
ZA201102119B (en) Improved antibody libraies
GB0815109D0 (en) Polydialkylsiloxane-bridged bi-photochromic molecules
GB0821100D0 (en) Antibodies
IL216097A0 (en) Anti-axl antibody
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
AU2013207589A1 (en) Anti-Siglec-15 Antibody
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
ZA201007976B (en) Anti-pirb antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB2473934B (en) Anti-VEEV antibody
GB0902916D0 (en) Antibody therapy
GB0911770D0 (en) Antibody
GB0903562D0 (en) RNA molecules
GB0915520D0 (en) Molecules
GB0911712D0 (en) Antibody

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)